Skip to main content

Table 2 Selected trials of chemoimmunotherapy with rituximab in CLL patients

From: Therapeutic advancement of chronic lymphocytic leukemia

Reference (year) Regimen Phase Number of patients Treatment status CR,% ORR,% Median PFS (months) Median OS (months)
Woyach, 2011 [17] FR (C) 2 51 Untreated 47 90 42 85
  FR (S)   53 Untreated 28 77   
Kay, 2007 [18] PCR 2 64 Untreated 41 91 32.6 Not Rep
Kay, 2010 [19] PR 2 33 Untreated 27 76 12 Not Rep
Reynolds, 2011 [20] PCR 3 92 20% Pretreated 7 49 NR NR
  FCR   92 20% Pretreated 14 59 NR NR
Wierda, 2011 [21] FBR 1/2 14 Untreated 36 93 Not Rep Not Rep
Bosch, 2011 [23] R-FCM 2 72 Untreated 82 93 Not Rep Not Rep
Jenke, 2011 [24] CHOP-R 2 26 Pretreated, F-ref 0 54 11 27
    15 Pretreated, RT 7 67 15 27
    15 Pretreated, AIC 0 82 14 50
  1. Abbreviations: AIC, autoimmune cytopenia; CHOP-R, cyclophosphamide, adriamycin, vincristine and prednisone plus rituximab; CR, complete response; FBR, fludarabine, bendamustine, and rituximab; FR (C), fludarabine, rituximab, concurrent; FR (S), fludarabine, rituximab, sequential; FCR, fludarabine, cyclophosphamide, rituximab; F-ref, fludarabine-refractory; NR, not researched; Not Rep, not reported; ORR, overall response rate; OS, overall survival; PCR, penostatin cyclophosphamide, rituximab; PFS, progression-free survival; R-FCM, rituximab, fludarabine, cyclophosphamide, mitoxantrone; RT: Richter’s transformation.